Member Info for SGD27

RM expecting "first part results at the end of June" suggests there may have been a slight delay. I'm wondering if they paused recruitment while they got the faster turnaround virus test in place, so that it could be applied to as many subjects as possible.

I'm referring to the amendment dated 22/04/2020 here :

https://www.hra.nhs.uk/covid-19-research/approved-covid-19-research/281317/

It's there now, approx 57 minutes in.

https://www.globalplayer.com/catchup/lbc/uk/b8FPfUZ/

Thanks PaleAle & Rgh98, I assume it will end up here? :

https://www.globalplayer.com/catchup/lbc/uk/b8FPfUZ/

@NOZ, Take your mind off it by doing some background reading. This isn't a bad place to start for new investors :

https://www.goodreads.com/book/show/2327764.The_Naked_Trader

https://www.bbc.co.uk/programmes/m000hybb

Just for reference :
https://www.bbc.co.uk/programmes/m000hybb

"Remdesivir is helpful but not a wonder drug, say researchers"

https://www.bmj.com/content/bmj/369/bmj.m1798.full.pdf

If Arix have enough spare cash, it might make sense for them to buy back the Woodford shares themselves!

Here's a couple of articles of interest on MMs :

https://www.investorschronicle.co.uk/shares/2018/11/09/the-truth-about-market-makers/

and

https://www.investorschronicle.co.uk/shares/2019/10/24/shake-your-market-maker/

Not looking great, according to this review :

https://emcrit.org/pulmcrit/wang-remdesivir/

I hadn't come across this one before. Interferon Alpha 14, injected or inhaled. It's at a very early stage of development.

https://www.pharmiweb.com/pwtoday-story/uk-biotech-company-announces-discovery-of-novel-potential-covid-19-treatments

A brief mention here :

https://www.morningstar.co.uk/uk/news/AN_1588268428551657100/uk-trading-update-summary-batm-ramps-up-covid-19-test-production.aspx

But note that this trial does not have a Data Monitoring Committee.

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB

Pharmaxis quarterly newsletter today :

http://www.pharmaxis.com.au/assets/Documents/pdf/02020/ASX/2020-04-30-Quarterly-Shareholder-Update-March-Quarter-2020-Final.pdf

LOXL2 news :
- "further phase 1 dosing study" completed
- partnering talks continuing

Sorry, PJ, I don't do private messaging - too mean to pay for the premium service.

Well spotted Forest24 (& Bosi for flagging the earlier amendment yesterday).

My first thought was - would an over-65 be able to cope with doing things this way?

Then I remembered - I am an over-65 :-(

Seriously, I think this is a great development. It's very innovative, and for that reason alone I think they'll have no problem getting publicity if they need it.

What does it imply for the original hospital-based trial? I take a mixed view. It can't have been ideal, or they wouldn't be making this adjustment. But it can't have been negative (bad reactions etc.), or they'd never be allowed to switch to home-based.

Regarding the results timetable, I'm not sure if the original 100 might be unblinded while the 120 follow-on is still in progress?

https://kalkinemedia.com/uk/news/two-buzzing-covid-19-aim-biotechnology-play-sng-and-etx

Yes, there is news from Gilead today :

https://www.reuters.com/article/us-health-coronavirus-gilead-remdesivir/gileads-remdesivir-meets-main-goal-of-trial-in-covid-19-patients-idUSKBN22B1T9

"In Gilead’s study, 62% of patients treated early were discharged from the hospital, compared with 49% of patients who were treated late, the company said."

This doesn't prove anything of course. Even if administering the drug is only producing a placebo effect, it's quite possible that an earlier-given placebo is more effective than a later-given one.

Double-blind is essential.

He'll say he's doesn't control the SP. Don't waste his time.

https://www.vo%78markets.co.uk/articles/vadim-alexandre-on-novacyt-synairgen-hemogenyx-and-polarean-plus-glen-goodman-3d49d3b